APA (7th ed.) Citation

G, F., MR, B., M, H. N., & JC, B. (2026). UV1 plus pembrolizumab in recurrent and metastatic head and neck squamous cell carcinoma: Safe, immunogenic, but lacking efficacy. Translational cancer research, 15(3), 140. https://doi.org/10.21037/tcr-2025-1-2689

Chicago Style (17th ed.) Citation

G, Flores, Buchakjian MR, Heft Neal M, and Brenner JC. "UV1 Plus Pembrolizumab in Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma: Safe, Immunogenic, but Lacking Efficacy." Translational Cancer Research 15, no. 3 (2026): 140. https://doi.org/10.21037/tcr-2025-1-2689.

MLA (9th ed.) Citation

G, Flores, et al. "UV1 Plus Pembrolizumab in Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma: Safe, Immunogenic, but Lacking Efficacy." Translational Cancer Research, vol. 15, no. 3, 2026, p. 140, https://doi.org/10.21037/tcr-2025-1-2689.